Scarica l'app Stockscreener
1.63
3.16%
0.05
Pre-mercato:
1.65
0.02
+1.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$1.58
Aprire:
$1.59
Volume 24 ore:
7.65M
Relative Volume:
0.96
Capitalizzazione di mercato:
$492.11M
Reddito:
$188.87M
Utile/perdita netta:
$-400.38M
Rapporto P/E:
-1.0867
EPS:
-1.5
Flusso di cassa netto:
$-260.90M
1 W Prestazione:
-11.41%
1M Prestazione:
-26.24%
6M Prestazione:
+22.56%
1 anno Prestazione:
-12.83%
Intervallo 1D:
$1.54
$1.71
Intervallo di 1 settimana:
$1.51
$2.00
Portata 52W:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.63 | 477.01M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
PacBio (PACB) Q4 2025 Earnings Call Transcript - AOL.com
Pacific Biosciences of California : PACB Q4 2025 Earning Prepared Remarks - marketscreener.com
Exit Recap: Should I invest in Clene Inc before earningsEarnings Risk Summary & Stepwise Swing Trade Plans - baoquankhu1.vn
Pacific Biosciences Faces Turbulent Market Amid Industry Shifts - timothysykes.com
Aug Drivers: Will Pacific Biosciences of California Inc outperform tech stocks2025 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Is Pacific Biosciences of California Inc. stock a falling knife or bargain buy2025 Stock Rankings & Long Hold Capital Preservation Tips - mfd.ru
Will Pacific Biosciences of California Inc. outperform tech stocksJuly 2025 Reactions & High Win Rate Trade Alerts - mfd.ru
How does Pacific Biosciences of California Inc. compare to its peersJuly 2025 Short Interest & Risk Managed Investment Signals - mfd.ru
Pacific Biosciences of California (PACB) reports Q4 loss, beats revenue estimates - MSN
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2025 Earnings Call Transcript - Insider Monkey
Slammed 28% Pacific Biosciences of California, Inc. (NASDAQ:PACB) Screens Well Here But There Might Be A Catch - 富途牛牛
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 6.8%What's Next? - MarketBeat
Pacific Biosciences of California: Navigating Market Waves Amid Revenue Hurdles - StocksToTrade
PACB Q4 Deep Dive: Consumables and Clinical Adoption Drive Growth as SparkNex Launch Nears - Finviz
PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up - TradingView
Pacific Biosciences of California, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
PacBio Q4 2025 slides: Revenue growth and margin expansion driven by human genomics - Investing.com Canada
Pacific Biosciences's Q4 And Full-Year Revenue Improves - Nasdaq
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results - The Globe and Mail
Pacific Biosciences of California Inc (PACB) Q4 2025 Earnings Ca - GuruFocus
PacBio (NASDAQ:PACB) Reports Strong Q4 CY2025 - The Globe and Mail
Pacific Biosciences of California Q4 2025 Earnings Call Transcript - MarketBeat
Pacific Biosciences of California Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Pacific Biosciences beats Q4 2025 forecasts By Investing.com - Investing.com Canada
PACB: Record consumable growth and SparkNex launch set stage for 8% revenue growth in 2026 - TradingView
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Announces Earnings Results - MarketBeat
Pacific Biosciences: Q4 Earnings Snapshot - kens5.com
PacBio (PACB) Surpasses Q4 Revenue Expectations Amid Strategic E - GuruFocus
PacBio (NASDAQ: PACB) lifts 2025 revenue but posts large restructuring-driven loss - Stock Titan
Pacific Biosciences of California joins iHope to expand genomic sequencing access - Traders Union
PacBio tech joins iHope to help rare disease patients get answers - Stock Titan
Valuation Update: Is Freedom Holding Corp in a bullish channelEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
What analyst consensus says on Pacific Biosciences of California Inc. stockRate Hike & Accurate Technical Buy Alerts - mfd.ru
Pacific Biosciences: Fourth Quarter Earnings Overview - Bitget
How strong is Pacific Biosciences of California Inc. stock revenue growth2025 Stock Rankings & Risk Controlled Stock Alerts - mfd.ru
PacBio Earnings: What To Look For From PACB - Finviz
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt - 富途牛牛
How The Narrative Around Pacific Biosciences Of California (PACB) Is Shifting As Assumptions Evolve - Yahoo Finance
Buyback Watch: Will BIIB benefit from sector rotationPortfolio Value Summary & Daily Growth Stock Investment Tips - baoquankhu1.vn
Pacific Biosciences of California (PACB) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Risk Recap: Can Pacific Biosciences of California Inc. reach all time highs this yearWeekly Earnings Recap & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Pacific Biosciences Announces Interim Leadership Role Realignment - The Globe and Mail
Pacific Biosciences showcases automation options at SLAS2026 - Traders Union
PacBio sells short-read DNA sequencing assets to Illumina for $48.1m - Investing.com Nigeria
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 7.7%Here's Why - MarketBeat
Pacific Biosciences Sees Strategic Maneuvers Amid Financial Woes - StocksToTrade
Pacific Biosciences of California Closes $48.1 Million Sale of DNA Sequencing Assets to Illumina - marketscreener.com
PacBio (PACB) Finalizes Asset Sale to Illumina, Secures $48.1 Mi - GuruFocus
Pacific Biosciences Strengthens Balance Sheet via Asset Sale - TipRanks
Pacific Biosciences of California Signs Asset Purchase Agreement With Illumina Cambridge - TradingView
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):